<code id='D3FC5386D1'></code><style id='D3FC5386D1'></style>
    • <acronym id='D3FC5386D1'></acronym>
      <center id='D3FC5386D1'><center id='D3FC5386D1'><tfoot id='D3FC5386D1'></tfoot></center><abbr id='D3FC5386D1'><dir id='D3FC5386D1'><tfoot id='D3FC5386D1'></tfoot><noframes id='D3FC5386D1'>

    • <optgroup id='D3FC5386D1'><strike id='D3FC5386D1'><sup id='D3FC5386D1'></sup></strike><code id='D3FC5386D1'></code></optgroup>
        1. <b id='D3FC5386D1'><label id='D3FC5386D1'><select id='D3FC5386D1'><dt id='D3FC5386D1'><span id='D3FC5386D1'></span></dt></select></label></b><u id='D3FC5386D1'></u>
          <i id='D3FC5386D1'><strike id='D3FC5386D1'><tt id='D3FC5386D1'><pre id='D3FC5386D1'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          comprehensive

          author:knowledge    - browse:558
          Peter Marks. -- health coverage from STAT
          Peter Marks, Director of the Center for Biologics Evaluation and Research at the Food and Drug Administration. Susan Walsh-Pool/Getty Images

          Peter Marks wants drug developers to ask more stupid questions.

          It’s part of the top Food and Drug Administration official’s plan to reinvigorate gene therapy, a field that has struggled despite significant technological advances. Some companies are shelving programs or going out of business, even when they have promising data. 

          advertisement

          The problems are numerous: The diseases are often exceptionally rare, limiting the potential market. Manufacturing at commercial quality is complex and expensive. Proving a drug works can be difficult, because there may be too few patients to run a traditional randomized study. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus